methylprednisolone: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
methylprednisolone: clinical details
Prescribing considerations
- Confirm whether therapy is anti-inflammatory, immunosuppressive or adrenal replacement, as withdrawal and stress-management implications differ.
- Assess infection and vaccination history, including tuberculosis, chickenpox, shingles and measles exposure.
- Review ongoing need and toxicity regularly; issue appropriate steroid safety information and documentation.
- Consider enhanced risks in older people and children, including osteoporosis, infection, metabolic effects and growth suppression.
Contraindications and cautions
- Hypersensitivity to methylprednisolone or an excipient
- Systemic fungal infection
- Systemic infection without appropriate anti-infective treatment
- Live or live-attenuated vaccination during immunosuppressive corticosteroid exposure
- Selected tablets contain lactose, derived from cow’s milk, and sucrose; assess relevant allergy and hereditary carbohydrate-intolerance risks.
Monitoring
- Clinical response and signs of infection
- Blood pressure, fluid status and weight
- Blood glucose, particularly with diabetes or metabolic risk
- Electrolytes, especially potassium where clinically relevant
- Mood, sleep, cognition and suicidal thinking
- Visual symptoms and ocular complications
- Bone health, muscle effects and growth in children during prolonged exposure
- HPA-axis suppression and withdrawal risk
- INR or prothrombin time with vitamin K antagonists
Clinical pharmacology
Methylprednisolone is a synthetic glucocorticoid that activates intracellular glucocorticoid receptors and modifies transcription of inflammatory and immune-response genes. Oral absorption is high; hepatic metabolism is mainly through CYP3A4, creating clinically important inducer and inhibitor interactions.
Formulation and product differences
- The selected product is a conventional oral tablet containing lactose, sucrose, maize starch and calcium stearate.
- This page does not cover injectable methylprednisolone salts or depot preparations, whose routes, excipients and product particulars differ.
methylprednisolone preparations and strengths
Tablet
Route: Oral
Strengths: 2 mg, 4 mg, 16 mg, 100 mg
methylprednisolone interactions
Check prescribed, over-the-counter and herbal products with a pharmacist or prescriber. Important interactions include:
Ritonavir, cobicistat and other strong CYP3A inhibitors
May increase methylprednisolone exposure and systemic corticosteroid adverse effects.
Clarithromycin, erythromycin, itraconazole or ketoconazole
May slow methylprednisolone metabolism and increase toxicity risk.
Rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital or primidone
May increase methylprednisolone clearance and reduce its clinical effect.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.